From 1 April 2026, DMC Healthcare will deliver the North and North East Lincolnshire Community Dermatology Service, taking over from HCRG Care Group.
This page provides information for patients currently receiving care or waiting for an appointment, including answers to common questions about the change.
Our aim is to ensure that care continues safely and smoothly with minimal disruption.
From 1 April 2026, DMC Healthcare will provide the Community Dermatology Service for patients in North and North East Lincolnshire.
For patients currently receiving treatment or waiting for an appointment:
If any changes to your appointment are required, the service team will contact you directly.
We at DMC Healthcare are a clinically led provider delivering NHS services across the UK since 1967, and we are registered with the Care Quality Commission (CQC). We work in partnership with the NHS to provide a range of community and specialist healthcare services. You can find out more at www.dmchealthcare.co.uk.
To ensure continuity of care, relevant medical records will be securely transferred to DMC Healthcare.
This allows our clinical team to understand your medical history and continue your treatment safely. Some records may be securely shared before 1 April 2026 so appointments can continue without delay once we begin delivering the service.
All information will be handled securely and confidentially in accordance with UK data protection legislation.
You have rights regarding your personal data, including the right to:
For more information about how we manage patient information, please read our Privacy Policy.
If you would like to access medical records relating to your care before 1 April 2026, please contact HCRG Care Group: accesstorecordsteam@hcrgcaregroup.com
Healthcare services are regularly reviewed and commissioned to ensure patients receive high-quality, safe, and effective care. Following a commissioning process, a new provider has been appointed to deliver this service.
The new provider will take over the service from 1 April 2026. We are working closely together to ensure the transition is smooth and causes minimal disruption for patients.
No action is required from you. Your care will continue as normal and you do not need to re-register for the service.
Yes. All existing appointments and referrals will remain valid. If anything changes regarding your appointment, you will be contacted directly.
Your current care plan and treatment will continue. Any future changes to your care will always be discussed with you by a clinician.
Your medical records will be securely transferred to the new provider so that your care can continue safely and effectively.
All information will continue to be handled in accordance with data protection and confidentiality regulations.
Some staff may remain the same, while others may be new members of the team. All clinicians working in the service will be appropriately qualified and trained.
Most services will continue to be delivered from the same location and with similar opening hours. If any changes are planned, patients will be informed in advance.
Appointments can continue to be booked in the usual way. If the booking process changes, we will let patients know as soon as possible.
If you have any questions about the service or the transition, please contact:
Service Contact Details
Phone: 020 7635 1013
Email: dmc.administration@nhs.net
We welcome feedback from patients. If you wish to raise a concern or make a complaint, please contact the service using the details above and ask to speak to the Patient Experience Team.
From 1 April 2026, DMC Healthcare will manage your dermatology biologic treatment on behalf of the Humber and North Yorkshire Integrated Care Board (HNY ICB). This change will not affect your eligibility, medicine supply, or clinical monitoring.
Your biologic medicines will continue to be delivered via a specialist homecare service, either Lloyds Pharmacy Homecare or Healthnet Pharmacy, depending on your medicine.
Sometimes the brand of your biologic may change to a biosimilar, which is clinically equivalent and approved by UK regulators. Any brand change does not affect your treatment — you will continue to receive the same medicine type, dose, and for the same condition.
Your blood tests and clinical reviews will continue as usual. We will contact you if any further information is needed to ensure your care continues smoothly.
No. We will work closely with the NHS and the homecare provider to ensure there is no interruption to your treatment or homecare deliveries.
From 1 April 2026, your dermatology biologic care will be managed DMC Healthcare, working on behalf of Humber and North Yorkshire Integrated Care Board (HNY ICB).
Your biologic medicine will be delivered to your home by a specialist homecare service. We will use:
The homecare provider will contact you to arrange deliveries.
A biologic medicine is a type of treatment made using living cells. Biologics are used for inflammatory skin conditions such as psoriasis and other dermatology conditions when standard treatments have not worked well enough.
A bioequivalent (also known as a biosimilar) is a medicine that is highly similar to an existing biologic medicine. It has been tested and approved to ensure it works in the same way and is as safe and effective as the original brand.
Yes. Your biologic may be supplied under a different brand name, including a biosimilar version. This is normal NHS practice and supports best value prescribing.
No. A change in brand does not mean your treatment has changed in a way that affects your care. The medicine is considered clinically equivalent and is used in the same way for the same condition.
Not usually. Consent is obtained when you start biologic treatment and includes discussion that the brand may change over time. If there is a specific clinical reason to discuss your treatment again, we will do so.
If you have concerns, please contact the dermatology team. We can explain the change and answer your questions. If there is a rare clinical reason why you should not switch, this will be reviewed by the clinical team.
Possibly. Some brands have different packaging or injection devices. If your device changes, the homecare provider and/or the dermatology team will support you with training and guidance.
If your delivery does not arrive when expected, contact the homecare provider directly using the number they give you. You can also contact the dermatology team. We have escalation arrangements in place to prevent missed doses.
Do not use the medicine. Contact the homecare provider immediately. They will arrange replacement and provide advice. You can also inform the dermatology team.
Most biologic medicines must be stored in a refrigerator. Your homecare provider will provide storage instructions. If you are unsure, contact the homecare provider or the dermatology team.
Monitoring depends on your biologic medicine but usually includes blood tests and clinic review appointments at intervals set by the clinical team. Monitoring is important to ensure your treatment remains safe and effective.
Biologic medicines can affect the immune system. If you feel unwell, develop a fever, signs of infection, or are concerned about side effects, contact the dermatology team promptly. If you are seriously unwell, seek urgent medical attention via NHS 111 or 999.
If you wish to make a complaint, you can contact dmc.feedback@nhs.net.
No. Biologic medicines for dermatology are specialist medicines. They will continue to be prescribed by the specialist dermatology team, not your GP.
Clinical effectiveness means ensuring that all aspects of service delivery are designed to provide the best outcomes for patients. This is achieved by ensuring that the right care is delivered to the right person at the right time they are in need and in the correct setting.
A patient’s information should always be up to date and correct on any systems used. It should also be confidential through correct storage and management of data.
Risk Management involves having robust systems in place to understand, monitor and minimise the risks to patients and staff and to learn from mistakes. When things go wrong in the delivery of care, our staff teams should feel safe admitting it and be able to learn and share what they have learnt, which embeds change in practice.
Communication with patients and the public is essential to gain insight on the quality of care we deliver, and any possible problems that can result. Public involvement is equally as important to ensure that patient and public feedback is used to improve services into day-to-day practice for better patient outcomes.
This encompasses the provision of appropriate support to enable staff to be competent in doing their jobs and to develop their skills so that they are up to date. Professional development needs to continue through lifelong learning.
This ensures the organisation recruits highly skilled staff and aligns them with the correct job roles. Staff are supported in professional development and to gain and improve their skills.
The aim of the audit process is to ensure that clinical practice is continuously monitored and that deficiencies in relation to set standards of care are remedied. Research goes alongside audits to pioneer best practice improvements.
